₨ 4,665.78
MBBS
Eskinase Injection 1.5 MIU 1 Vial
- Does this requires a prescription ? Yes
- Generic Name: Streptokinase
- Manufactured by : Medinet Pharmaceuticals
- Drug Strength : 1.5 MIU
- Drug Form : Injection
- Pack Size : 1 vial
- Product SKU : pg_7825_10888
Eskinase Injection contains Streptokinase | belongs to Fibrinolytic
Alternate brands of Eskinase Injection 1.5 MIU 1 Vial
| Brand Name | Price | Savings |
|---|---|---|
| Unitinase Injection 1.5 MIU 1 Vial | ₨ 4,370.00 | You can save 295.78 |
| Streptokinase Injection 1.5 MIU 1 Amp | ₨ 4,738.00 | You will pay -72.22 more |
| Streptase Injection 1.5 MIU 1 Amp | ₨ 5,765.00 | You will pay -1099.22 more |
| Durakinase Injection 1.5 MIU 1 Vial | ₨ 4,388.00 | You can save 277.78 |
| Diclair-ST Injection 1.5 MIU 1 Vial | ₨ 4,900.00 | You will pay -234.22 more |
How it works
This medicine increases the formation of an enzyme (plasmin) which is responsible for the breakdown of blood clots.
Side effects
Major & minor side effects for Eskinase Injection 1.5 MIU 1 Vial
- Skin Rash severe
- Flushing severe
- Skin blistering severe
- Shortness of breath severe
- Low blood pressure severe
- Nosebleed
- Headache
- Muscle pain and weakness
- Diarrhea
- Chills
- Dizziness severe
Uses of Eskinase Injection 1.5 MIU 1 Vial
What is it prescribed for?
-
Acute myocardial infarction
This medicine is used in the treatment and prevention of a myocardial infarction (heart attack). It dissolves blood clots and promotes a smooth flow of blood, thus reducing the strain on the heart.
-
Deep Vein Thrombosis
This medicine is used in the treatment and prevention of deep vein thrombosis (blood clot in the deep veins of the body).
-
Pulmonary Embolism
This medicine is used in the treatment and prevention of pulmonary embolism (blood clot in the lung arteries).
-
Arterial thrombosis
This medicine is used in the treatment and prevention of arterial thrombosis (blood clot in the arteries).
Concerns
Frequently asked questions
-
Onset of action
On intravenous administration, the onset of action of this medicine is immediate.
-
Duration of Effect
The effect of this medicine lasts for an average duration of 4 to 12 hours.
-
Safe with Alchohol?
Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
-
Is it habit forming?
No habit forming tendency has been reported.
-
Usage in pregnancy?
This medicine is not recommended for use in pregnant women except in life-threatening conditions. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may prescribe a safer alternative based on your clinical condition.
-
Usage while breast-feeding?
This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue breastfeeding for a short period of time, based on your clinical condition. Replacement with a suitable alternative may be necessary in some cases.
When not to use?
-
Internal bleeding
This medicine is not recommended for use in patients with a known history of active or recent internal bleeding since it may worsen the patient's condition.
-
Intracranial neoplasm
This medicine is not recommended for use in patients with a known history of an intracranial tumor due to the increased risk of excessive bleeding.
-
Allergy
This medicine is not recommended for use in patients with a known allergy to Eskinase Injection 1.5 MIU 1 Vial or any other inactive ingredients present along with it.
-
Surgery
This medicine is not recommended for use in patients with a recent history of intracranial or intraspinal surgery due to the increased risk of excessive bleeding.
-
Uncontrolled blood pressure
This medicine is not recommended for use in patients with a known history of uncontrolled blood pressure since it may worsen the patient's condition.
-
Head trauma
This medicine is not recommended for use in patients with a recent history of head trauma due to the increased risk of excessive bleeding.
-
Acute pancreatitis
This medicine is not recommended for use in patients with a known history of acute pancreatitis since it may worsen the patient's condition.
Warnings
-
Pregnancy
This medicine is not recommended for use in pregnant women except in life-threatening conditions. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may prescribe a safer alternative based on your clinical condition.
-
Breast-feeding
This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue breastfeeding for a short period of time, based on your clinical condition. Replacement with a suitable alternative may be necessary in some cases.
-
Head injury
This medicine is not recommended for use in patients with a recent history of head injury due to the increased risk of excessive bleeding. Replacement with a suitable alternative should be considered under your doctor's supervision.
-
Bleeding disorders
This medicine is not recommended for use in patients with a known history of bleeding disorders due to the increased risk of worsening of the patient's condition.
-
Kidney diseases
This medicine should be used with extreme caution in patients with a known history of kidney diseases due to the increased risk of worsening of the patient's condition. Frequent monitoring of kidney function is recommended for such patients. Appropriate dose adjustments or replacement with a suitable alternative may be necessary based on the clinical condition.
-
Hepatic diseases
This medicine should be used with extreme caution in patients with a known history of hepatic diseases due to the increased risk of worsening of the patient's condition. Frequent monitoring of liver function is recommended for such patients. Appropriate dose adjustments or replacement with a suitable alternative may be necessary based on the clinical condition.
-
Cerebrovascular diseases
This medicine should be used with extreme caution in patients with a known history of cerebrovascular diseases due to the increased risk of worsening of the patient's condition. Appropriate dose adjustments or replacement with a suitable alternative may be necessary based on the clinical condition.
-
Surgey
This medicine is not recommended for use in patients with a recent history of a surgery due to the increased risk of excessive bleeding.
-
High blood pressure
This medicine should be used with extreme caution in patients with a known history hypertension (high blood pressure) due to the increased risk of worsening of the patient's condition. Frequent monitoring of blood pressure is recommended for such patients. Appropriate dose adjustments or replacement with a suitable alternative may be necessary based on the clinical condition.
Dosage
-
Missed Dose
Since this medicine is administered in the hospital or clinical setting by a qualified healthcare professional, the likelihood of missing a dose is very low.
-
Overdose
Since this medicine is administered in the hospital or clinical setting by a qualified healthcare professional, the likelihood of an overdose is very low. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.
Interactions
Interaction with Medicines- Citalopram moderate
- Fluoxetine moderate
- Lisinopril moderate
- Diclofenac moderate
- Anticoagulants severe
-
moderate
This medicine should be used with caution in patients with lung diseases since it may worsen the patient's condition. Close monitoring of lung function is recommended for such patients. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.
-
severe
This medicine is not recommended for use in patients with bleeding disorders since it may worsen the patient's condition. Replacement with a suitable alternative should be considered under your doctor's supervision.
-
severe
This medicine is not recommended for use in patients with uncontrolled hypertension since it may worsen the patient's condition. Replacement with a suitable alternative should be considered under your doctor's supervision.
General Instructions
This medicine is administered by a qualified healthcare professional in the clinical or hospital setting. Carefully follow all the instructions given by your doctor. Inform the doctor if you have an allergy to this medicine. Report to the doctor all your current medicines as well as your medical conditions before receiving this medicine.
Other details
- Usage does not depend on food timings
- To be taken as instructed by doctor
- Does not cause sleepiness
References
- practo - Streptokinase [Internet]. Available from: https://www.practo.com/medicine-info/streptokinase-729-api [cited 12/8/2020]. 30 Oct 2017
How to use Eskinase Injection 1.5 MIU 1 Vial
IM: Do not administer by IM injection. IV: For IV or intra-coronary use only. Infusion pump is required. Use in-line filter gt;0.8 micron. Acute MI: Dilute two 750000 unit vials of streptokinase with 5 mL D5W each, gently swirl to dissolve. Add this dose of the 1.5 million units to 150 mL D5W. This should be infused over 60 min; an in-line filter gt;0.45 micron should be used. Acute pulmonary embolism: Dilute four 750000 unit vials of streptokinase with 5 mL dextrose 5% in water (D5W) each, gently swirl to dissolve. Add this dose of 3 million units to 250 mL D5W, an in-line filter gt; 0.45 micron should be used. Administer 250000 units (23 mL) over 30 min followed by 100000 units /hour (9 mL/hour) for 24 hours. Thrombosis: Administer 250000 units to start, then 100000 units/hour for 24-72 hours depending on location. Cannula occlusion: 250000 units into cannula, clamp for 2 hours then aspirate contents and flush with NS.
Compatibility: Stable in D5W, NS. Incompatible with dextrans.
Stability: Intact vials should be stored at room temperature. Stability of parenteral admixture at room temperature (25°C) is 8 hours and at refrigeration (4°C) is 24 hours. Reconstituted solutions should be refrigerated and are stable for 24 hours.
UNLICENSED USE
Children: Intravascular thrombosis: IV infusion. 1 mth-12 yr, initially 2500-4000 units/kg over 30 minutes, followed by continuous IV infusion of 500-1000 units/kg/hr for up to 3 days until reperfusion occurs; 12-18 yr, initially 250 000 units over 30 minutes, followed by continuous IV infusion of 100000 units/hr for up to 3 days until reperfusion occurs.
what are the adverse effects of Eskinase Injection 1.5 MIU 1 Vial?
Hypotension, arrhythmias. Febrile reactions, anaphylaxis (rare). Haemorrhage. Minor bleeding from puncture sites, severe haemorrhage. Pulmonary oedema. Cholesterol embolism.
What happens if I miss a dose of Eskinase Injection 1.5 MIU 1 Vial?
Adults: Acute myocardial infarction: Single dose of 1.5 million IU by IV infusion over 1 hr.
Dissolution of other thrombi and emboli: Loading dose of 250,000 IU by IV infusion, then 100,000 IU per hr for 24-72 hr, depending on condition; see literature.
Acute pulmonary embolism: 3 million unit dose over 24 hr.
One of the following licensed pharmacy from the nearest location will deliver Eskinase Injection 1.5 MIU 1 Vial. The details of the licensed pharmacy shall be shared once you request the drugs and the respective pharmacy accepts your request based on valid prescription and availability.
Questions and Answers
There are no questions yet. Be the first to ask a question about this product.
Related products
Products listed on medicalstore.com.pk are 100% genuine and sourced from licensed pharmacies.
We work hard to bring you unimaginable discounts without compromising on quality.
We uses SSL (standard security technology) to ensure data privacy of all our customers.
Reviews
There are no reviews yet.